SCHEMBL66839

SCHEMBL66839

B(Oc1ccc(-c2ccccc2)cc1)Oc1ccc(-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 1/20 0.45
CYP1A2 P05177 2/20 0.42
TAAR1 Q96RJ0 2/20 0.42
MAPK1 P28482 1/20 0.42
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MMP3 P08254 1/20 0.42
BCL2L1 Q07817 1/20 0.42
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
LSS P48449 1/20 0.39
IDO1 P14902 2/20 0.38
AGXT P21549 2/20 0.38
LTA4H P09960 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8885 0.83 LTA4H (0.50) ALDH1A1CA1CA2CA9TAAR1
SCHEMBL3422941 0.83 ESR1 (0.52) CA1CA2CA9CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL693111 0.80 LTA4H (0.47) ALDH1A1CA1CA2CA9TAAR1
SCHEMBL14117990 0.80 ALDH1A1 (0.43) ALDH1A1CYP1A2MAPK1CYP3A4CYP2C9
SCHEMBL25661896 0.80 MMP3 (0.44) ALDH1A1CA1CA2CA9CYP1A2
SCHEMBL819908 0.80 MMP3 (0.44) ALDH1A1CA1CA2CA9CYP1A2
SCHEMBL25661898 0.80 MMP3 (0.44) ALDH1A1CA1CA2CA9CYP1A2
SCHEMBL25661900 0.80 MMP3 (0.44) ALDH1A1CA1CA2CA9CYP1A2
SCHEMBL2510402 0.80 ESR1 (0.55) ALDH1A1CA1CA2CA9CYP1A2
SCHEMBL3684663 0.80 ESR1 (0.55) ALDH1A1CA1CA2CA9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117126152-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 CN disclosed
US-9287512-B2 Organic electroluminescent compounds, layers and organic electroluminescent device using the same ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2016-03-15 US disclosed
EP-2415773-B1 ORGANIC ELECTRONIC DEVICE, COMPOUNDS FOR SAME, AND TERMINAL DUK SAN NEOLUX CO LTD (KR) 2016-02-17 EP disclosed
US-9233923-B2 Organic compounds for organic electronic devices and terminals DUK SAN NEOLUX CO., LTD. (KR) 2016-01-12 US disclosed
US-20150357583-A1 Novel Organic Electroluminescent Compounds, Layers and Organic Electroluminescent Device Using The Same DUPONT SPECIALTY MATERIALS KOREA LTD (KR) 2015-12-10 US disclosed
US-20150171346-A1 Novel Organic Electroluminescent Compounds and Organic Electroluminescent Device Using The Same ROHM & HAAS ELECT MAT (KR) 2015-06-18 US disclosed
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP disclosed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US disclosed
US-6291514-B1 Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-09-18 US disclosed
US-6288228-B1 DIAMINOTRIAZINE DERIVATIVES ABBOTT LABORATORIES 2001-09-11 US disclosed
WO-2000047194-A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR DIMENSIONAL PHARM INC (US) 2001-05-31 WO disclosed
US-6150362-A ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES ABBVIE INC. 2000-11-21 US disclosed
EP-1037886-A1 TRIAZINE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2000-09-27 EP disclosed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed
WO-2000047194-A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed
WO-1999031088-A1 TRIAZINE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 1999-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150171346-A1 Novel Organic Electroluminescent Compounds and Organic Electroluminescent Device Using The Same OR10J3, VDAC2, KCNN2 ALDH1A1 590/4885CA1 3326/4885CA2 1595/4885
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 ALDH1A1 3209/4885CA1 2080/4885CA2 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.